At Lilly COI, our intent is to transform clinical development through patient focused efforts, and explore open innovation methods to do so.
Our overall approach is multifaceted: We’re learning from patient advocates about how to use social media to connect online with patients, caregivers and communities to bring valuable insights into clinical research; we attend conferences and have hosted a workshop to drive shared learning and generate ideas; and, we’ve created public prototypes and put out the open LCOI-API to surface information about clinical trials. Most recently, we announced a collaboration with other pharma to develop a capability to enable patients to match to clinical trials.
We’ve also sought out opportunities to source innovative ideas to help move the industry towards a common goal of improving the patient experience. One such way has been our sponsorship and promotion of challenges.
The Latest: Patient Engagement App Challenge
In November we announced the winners for the Clinical Trial Redesign Challenge live at our Patients-at-the-Center of Clinical
Research conference. The challenge was for designers and developers to re-imagine clinical trial information in a patient-centric way, and to support patients who are considering enrolling in a study.
Continuing in our innovation work, we are excited to announce our joining with a number of partners to sponsor the Patient Engagement App Challenge. UBC, Enlight BioSciences the Partnership In Clinical Trials conference and Lilly COI are calling for innovative applications that can help patients who are in a clinical trial.
Advances in computational science and biology enable us to understand ourselves in ways that we could not just a few years ago. Co-founded in 2006 by Anne Wojcicki, wife of Google co-founder Sergey Brin, 23andMe has emerged in the digital age to provide a view of our personal genetics - all for less than $100!
23andMe is evidence of Moore’s Law at work, and, in addition to giving unprecedented insight into our personal genome, efforts like 23andMe have innovative potential to change the way drugs are found and developed.
Thanks to Moore’s law, the cost per Human Genome is falling rapidly. More…
The following blog post is by Jeri Burtchell.
Jeri is a renowned patient advocate, with first-hand experience participating in clinical trials. Her ideas, passion and willingness to share via her blog and in speaking engagements help to clarify how clinical research works, its value, and where there needs to be further focus on the needs of the patient.
The opinions expressed by Jeri are her own, and do not necessarily reflect those of the Lilly COI Team.
In mid 2007 I laid on my back staring at the ceiling, trying to talk myself out of suicide. After eight years of battling multiple sclerosis I was sure there was no hope of ever seeing an improvement in my quality of life. The thought of my family’s certain sorrow over my tragic death forced me to find an alternative. I pushed myself to make one last effort at self-advocacy and hopefully change my life. I was ready to entertain drastic measures.
Allow me to introduce myself. My name is Jeri Burtchell, but from 2007 until 2011 I was also known as Subject #0008. More…